Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNG1005 versus physician's best choice chemotherapy in HER2-negative breast cancer with leptomeningeal carcinomatosis
ChiCTR2200063734Phase 3Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2022
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel trevatide in breast cancer and Carcinomatous Meningitis (CM) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Overall survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
paclitaxel trevatide
03
Conditions
breast cancerCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on ChiCTR2200063734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063734.